Efficacy, safety, and tolerability of inhaled levodopa (CVT-301) across age, timing of motor fluctuations, and treatment initiation in Parkinson’s disease: Pooled analysis of three phase 3 trials
Efficacy, safety, and tolerability of inhaled levodopa (CVT-301) across age, timing of motor fluctuations, and treatment initiation in Parkinson’s disease: Pooled analysis of three phase 3 trials. // Parkinsonism & Related Disorders. – URL: https://www.sciencedirect.com/science/article/pii/S1353802026008746?dgcid=rss_sd_all
Efficacy, safety, and tolerability of inhaled levodopa (CVT-301) across age, timing of motor fluctuations, and treatment initiation in Parkinson’s disease: Pooled analysis of three phase 3 trials. Parkinsonism & Related Disorders. https://www.sciencedirect.com/science/article/pii/S1353802026008746?dgcid=rss_sd_all
“Efficacy, safety, and tolerability of inhaled levodopa (CVT-301) across age, timing of motor fluctuations, and treatment initiation in Parkinson’s disease: Pooled analysis of three phase 3 trials.” Parkinsonism & Related Disorders.
@article{article61665,
title = {Efficacy, safety, and tolerability of inhaled levodopa (CVT-301) across age, timing of motor fluctuations, and treatment initiation in Parkinson’s disease: Pooled analysis of three phase 3 trials},
journal = {Parkinsonism \& Related Disorders},
url = {https://www.sciencedirect.com/science/article/pii/S1353802026008746?dgcid=rss_sd_all}
}
npj Aging, Published online: 19 November 2026; doi:10.1038/s41514-026-00570-8 Nicotinamide deficiency in the aqueous humor of patients with glaucoma revealed by LC-MS/MS
npj Aging, Published online: 19 November 2026; doi:10.1038/s41514-026-00566-4 Organ-specific proteomic aging in Chinese adults: 20-year clinical outcomes and metabolomic underpinnings